All In Biotech

Drug Trial Radar · NCT06789445

A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)

A Phase 1/2a Study of Subretinal Administration of OpCT-001 Photoreceptor Precursor Cells Derived From iPSCs in Patients With Primary Photoreceptor Disease

Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

54

Planned (sponsor's estimate)

Start

Mar 10, 2025

Primary completion

Oct 2029

Study completion Oct 2030

Sponsor

Lead sponsor
BlueRock TherapeuticsIndustry
Sponsor type
Industry
Collaborators
Bayer
First posted
Jan 23, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study OpCT-001-101 is a Phase 1/2a first-in-human, multisite, 2-part interventional study to evaluate the safety, tolerability, and the effect on clinical outcomes of OpCT-001 in approximately 54 adults with primary photoreceptor (PR) disease. Phase 1 focuses on safety and features a dose-escalation design. Phase 2 is designed to gather additional safety data and assess the effect of OpCT-001 on measures of visual function, functional vision, and anatomic measures of engraftment in different clinical subgroups.

Conditions

  • Primary Photoreceptor Disease
  • Retinitis Pigmentosa (RP)
  • Usher Syndrome
  • Inherited Retinal Disease (IRD)
  • Rod-Cone Dystrophy
  • Rod-Cone Disease
  • Retinal Degeneration
  • Cone-Rod Disease (C-RD)
  • Cone-Rod Dystrophy

Interventions

  • OpCT-001Biological

    Cell therapy product composed of photoreceptor precursor cells derived from human induced pluripotent stem cells (iPSCs).

  • OpCT-001Biological

    Cell therapy product composed of photoreceptor precursor cells derived from human iPSCs.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of ocular and non-ocular treatment-emergent adverse events (TEAEs) through the Week 52 visitTime frame: From OpCT-001 administration through the Week 52 visit

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • University of Southern California /Children's Hospital of Los Angeles

    Los Angeles, California · Recruiting

  • University of Miami, Bascom Palmer Eye Institute

    Miami, Florida · Recruiting

  • Mid Atlantic Retina/ Wills Eye

    Philadelphia, Pennsylvania · Recruiting

  • Retina Foundation of the Southwest

    Dallas, Texas · Recruiting

  • University of Wisconsin

    Madison, Wisconsin · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.